Last reviewed · How we verify
CTX310
At a glance
| Generic name | CTX310 |
|---|---|
| Sponsor | CRISPR Therapeutics AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |